Gilead to Present Late Breaking Data and Real World Evidence

– Three Oral Presentations and 30 Posters Across HBV, HCV, HDV, and Fibrosis, Including Late-Breaking Data on Hepcludex® in HDV, Demonstrate Gilead’s Commitment to Addressing Unmet Needs for...

Related Keywords

Foster City , California , United States , Tenofovir Alafenamide , Clinical Research For Hepatitis , Risk Of Development , Gilead Sciences In Liver Disease , Nasdaq , Gilead Sciences , World Health Organization , Exchange Commission , Gilead Sciences Inc , Viruses At Gilead Sciences , American Association , Liver Diseases , European Economic Area , Liver Meeting , Anu Osinusi , Vice President Clinical Research , Emerging Viruses , Marketing Authorization , Combination With Pegylated Interferon , Patients With Chronic Hepatitis Delta , Primary Endpoint Results From , Multicenter Study , Detected Resistance , Term Safety , Sofosbuvir Based Direct Acting Antivirals , Pediatric Patients , Hepatitisc Virus , Complexadic Study , Elimination Programs Leading , Global Action , Kidney Disease Risk , Advanced Fibrosis Due , Non Alcoholic Steatohepatitis , Between Liver Biomarkers , Clinical Outcomes , Primary Sclerosing Cholangitis , Retrospective Real World Study , Important Safety Information , Safety Information , Worsening Renal Impairment , Severe Hepatomegaly , During Treatment , Crcl Hepatic Impairment , Private Securities Litigation Reform Act , Quarterly Report , Gilead Logo , Markets ,